Gross JG, et al. - In this Diabetic Retinopathy Clinical Research Network, multicenter, randomized, clinical trial, researchers tested the effectiveness and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years for proliferative diabetic retinopathy (PDR). Findings revealed that visual acuity in most study eyes that completed follow-up was very good at 5 years and was comparable in both groups, although the loss to follow-up was relatively high. With PRP or ranibizumab, severe vision loss or serious PDR complications were uncommon. However, lower rates of developing vision-impairing diabetic macular edema and less visual field loss were observed in the ranibizumab group. The authors suggested considering patient-specific factors (eg, anticipated visit compliance, cost, and frequency of visits) when choosing treatment for a patient with PDR. Overall, results supported treatment with either antivascular endothelial growth factor therapy or PRP for patients with PDR.